LLYEli Lilly and CompanyRunning, no new patients
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 261 (final count)
- Started
- Feb 17, 2020
- Main results expected
- May 1, 2023
- Fully finished
- Jun 2030
- Results posted
- Jun 20, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)
Measured over: Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
PFS by BICR (With or Without Pembrolizumab)
Measured over: Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04194944 · record last updated 2026-10-21 · checked 2026-11-09 15:36 UTC